Klumper is replacing Eric van der Putten who leaves his role as CEO to become Chief Business Development Officer, responsible for driving new business opportunities and growing SMS Oncology’s client base.
“Our clients will benefit discussing their new cancer studies with Eric who brings to the table 30+ years of experience in running phase I and II cancer trials in close collaboration with the top tier of oncologists,” said new CEO Edwin Klumper. “His experience and operational insights will be of great value to our clients in achieving their objectives.”
Recipharm, Catalent, INC and PRA completed eye-catching IPOs in 2014. Which firms are likely follow suit in 2015?
Catering for low value, high volume customers as well as the growing number of firms developing complex...
Clinverse, Intertek and inVentiv are among the pharma services companies announcing new staff this week.